These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9004975)

  • 41. [Effect of hormone substitution therapy on AT III in women in the climacteric].
    Enzelsberger H; Heytmanek H; Kurz C; Metka M
    Zentralbl Gynakol; 1991; 113(11):639-44. PubMed ID: 1656654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estradiol delivery by vaginal rings: potential for hormone replacement therapy.
    Nash HA; Brache V; Alvarez-Sanchez F; Jackanicz TM; Harmon TM
    Maturitas; 1997 Jan; 26(1):27-33. PubMed ID: 9032744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Subdermal implantation of estradiol 17 beta (25 mg) in hysterectomized and ovariectomized women. Effects of increased serum estradiol level and neurovegetative climacteric complaints].
    Tsvetkov Ts; Tsvetkov K; Petkova U
    Akush Ginekol (Sofiia); 2001; 41 Suppl 4():11-2. PubMed ID: 11519312
    [No Abstract]   [Full Text] [Related]  

  • 44. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
    Savoca S; D'Agosta S; Lombardo G
    Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study of substitution hormonal therapy on cardiovascular diseases in post-menopausal women. A multicentric international collaboration (part I).
    Gutiu A; Dolis L; Peretianu D
    Rom J Intern Med; 2000-2001; 38-39():59-64. PubMed ID: 15529572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints.
    Gräser T; Römer T; Wiedey KD; Janaud A
    Climacteric; 2001 Dec; 4(4):332-42. PubMed ID: 11770190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of two hormone replacement regimens--influence on lipoproteins and bone mineral content.
    Hirvonen E; Elliesen J; Schmidt-Gollwitzer K
    Maturitas; 1990 Jun; 12(2):127-36. PubMed ID: 2147736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Oral or transdermal estrogen substitution therapy in climacteric?].
    Runnebaum B; Salbach B; von Holst T
    Geburtshilfe Frauenheilkd; 1994 Mar; 54(3):119-30. PubMed ID: 8188009
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women.
    Bassol S; Carranza-Lira S; Celis-Gonzalez C; Santoyo S; Murillo A; Martinez N; Santos J; Llaca V; de la Loza FR; Zarain J; da Fonseca AM; Camargos AF; Baracat EC; da Sá MF; Bayo J; Adaro L; Gurucharri C; Murga M; Siseles N; Sayegh F; Tempone A; Tempone LM; Tozzini RI; Boccanera R; Naranjo C; Sanchez F; Gomez G; Blanco S; Reyes-Marquez R; Albrecht G; Rios PC
    Maturitas; 2005 Mar; 50(3):189-95. PubMed ID: 15734600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Climacteric symptoms after oral and percutaneous hormone replacement therapy.
    Jensen PB; Jensen J; Riis BJ; Rødbro P; Strøm V; Christiansen C
    Maturitas; 1987 Nov; 9(3):207-15. PubMed ID: 2963205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Transdermal administration of estrogens in women with the postcastration and climacteric syndromes].
    Rotta L; Matĕchová E
    Cesk Gynekol; 1992 Sep; 57(7):336-40. PubMed ID: 1394497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The effect of hormonal replacement therapy on symptoms of climacteric syndrome and selected metabolic parameters].
    Kornaga E
    Ginekol Pol; 2001 Mar; 72(3):113-20. PubMed ID: 11398578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of estrogen replacement therapy on natural killer cell activity in postmenopausal women.
    Albrecht AE; Hartmann BW; Scholten C; Huber JC; Kalinowska W; Zielinski CC
    Maturitas; 1996 Nov; 25(3):217-22. PubMed ID: 8981339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo.
    Crona N; Samsioe G; Lindberg UB; Silfverstolpe G
    Maturitas; 1988 Mar; 9(4):303-8. PubMed ID: 3288845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Multicenter study of Klimonorm (R) by the Jenapharm firm for treating the climacteric syndrome].
    Czekanowski R; Stelmachow J; Radowicki S; Cekański A; Florczak M; Chlabicz P
    Ginekol Pol; 1995 Apr; 66(4):237-45. PubMed ID: 8529942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Complex effects of cavinton on climacteric symptoms].
    Kolarov G; Orbetsova M; Nalbanski B; Kamenov Z; Georgiev S; Filipov E; Petrova Iu; Marinov B; Georgiev G
    Akush Ginekol (Sofiia); 2001; 42(2):37-41. PubMed ID: 11799757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oestrogen therapy for the menopause.
    Studd J; Watson N; Henderson A
    Br J Psychiatry; 1990 Dec; 157():931-2. PubMed ID: 2289110
    [No Abstract]   [Full Text] [Related]  

  • 60. [Estrogen-progesterone replacement therapy in the postmenopause with cyproterone acetate, an antiandrogen progestin].
    Presl J
    Ceska Gynekol; 1995 Apr; 60(2):98-101. PubMed ID: 7767599
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.